Cell cultures, whether or not modified: — Cell therapy products
N325758 · 2022-05-25 — The tariff classification of YESCARTA® (Axicabtagene Ciloleucel) from the Netherlands
YESCARTA® (Axicabtagene Ciloleucel) is a CD19-directed genetically modified autologous T cell immunotherapy. It is indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma. In your letter, you stated that YESCARTA® is different than other cancer medicine because it is a personalized, single-infusion, autologous CAR T…
Not sure this code fits your product? HaiLang AI determines the US HTS code from a description in about a minute.
Classify a product